Sarizotan is a selective serotonin and dopamine reuptake inhibitor (SSDRI) that has been investigated for the treatment of conditions including major depressive disorder, anxiety, and obsessive-compulsive… Read more
Sarizotan is a selective serotonin and dopamine reuptake inhibitor (SSDRI) that has been investigated for the treatment of conditions including major depressive disorder, anxiety, and obsessive-compulsive disorder. This category of pharmaceutical reference standards includes the parent active ingredient, its enantiomers, and specific synthetic impurities such as N-Nitroso Sarizotan. Analytical laboratories utilize these high-quality materials to facilitate rigorous impurity profiling, metabolite identification, and method validation throughout the drug development lifecycle. By providing precise, characterized standards, these compounds enable accurate quantification and quality control, helping to ensure the safety and efficacy of final pharmaceutical formulations. These reference materials are essential for regulatory compliance and the development of robust analytical methods designed to monitor drug stability and purity in complex matrices.